Physician profile
Imola Daniel
NPI 1245460609
$15,962.88
in general payments reported to CMS, 2019-2025
67 companies · $3,882 in 2025
The $3,882 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $614 · 2021: $1,362 · 2022: $2,717 · 2023: $2,987 · 2024: $3,659 · 2025: $3,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $13.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,514.72 |
| Education | $13.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,386.72 | 2020-2025 | Dalvance, Linzess, Viberzi |
| Gilead Sciences, INC. | $1,275.34 | 2019-2025 | Biktarvy, Yeztugo |
| Astrazeneca Pharmaceuticals LP | $1,161.79 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,157.40 | 2019-2025 | |
| Lilly USA, LLC | $1,056.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $994.09 | 2020-2025 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $618.74 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $603.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $578.78 | 2020-2025 | |
| Novo Nordisk INC | $526.49 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $508.99 | 2019-2024 | Dovato, Apretude |
| Amgen INC. | $503.89 | 2019-2025 | Repatha, Repatha, Otezla |
| Alnylam Pharmaceuticals INC. | $472.68 | 2022-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $382.10 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $354.37 | 2019-2024 | Eliquis |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imola Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.